Abstract
Over the past few decades, remarkable advances have been achieved in cancer therapy, including chemotherapeutic agents, their mode of application and more broader therapeutic strategies. Promising new therapeutic targets have emerged in the past ten years as a result of recent advances in our understanding of the pathobiology of malignant cells, in particular, regarding functions of suppressor oncogene products. Among them, the agents that alter the cell cycle have recently been of particular interest, since cell cycle regulation is basic mechanism underlying cell fate, i.e., proliferation, differentiation or death. Furthermore, the human genome project has made possible the future development of so-called “tailor-made medicine”, i.e. the design of appropriate drugs for specific genetic profiles and application of drugs that are tailored to each tumor and patient. In this article, we will introduce and discuss recent progress in the development of agents that influence the cell cycle and their future potential in cancer therapy from three standpoints with our own experimental works; i) the inhibition of cell proliferation and / or induction of differentiation by cyclindependent kinase (cdk)-inhibitor, e.g. olomoucin, butyrolactone-I, ii) induction of apoptosis by directing “abortive cell cycle”, or the transient upregulation of cdk activity, e.g. flavopiridol, and iii) countering the development of drug resistance by adjunctive administration of cdk-inhibitors with conventional anti-cancer drug, e.g., p21-gene transfer with cisplatin. Conclusively none of these three approaches by itself is satisfactory, and that the effective cancer therapies will require the administration of several agents and / or methods under the design of their synergistic effects.
Keywords: anti-cancer drug, cell cycle, cyclin, cyclin-dependent kinase, inhibitor, apoptosis
Current Medicinal Chemistry
Title: [General Articles] Perspectives on Cancer Therapy: Cell Cycle Blockers and Perturbators
Volume: 10 Issue: 23
Author(s): Yoh Dobashi, Takuo Takehana and Akishi Ooi
Affiliation:
Keywords: anti-cancer drug, cell cycle, cyclin, cyclin-dependent kinase, inhibitor, apoptosis
Abstract: Over the past few decades, remarkable advances have been achieved in cancer therapy, including chemotherapeutic agents, their mode of application and more broader therapeutic strategies. Promising new therapeutic targets have emerged in the past ten years as a result of recent advances in our understanding of the pathobiology of malignant cells, in particular, regarding functions of suppressor oncogene products. Among them, the agents that alter the cell cycle have recently been of particular interest, since cell cycle regulation is basic mechanism underlying cell fate, i.e., proliferation, differentiation or death. Furthermore, the human genome project has made possible the future development of so-called “tailor-made medicine”, i.e. the design of appropriate drugs for specific genetic profiles and application of drugs that are tailored to each tumor and patient. In this article, we will introduce and discuss recent progress in the development of agents that influence the cell cycle and their future potential in cancer therapy from three standpoints with our own experimental works; i) the inhibition of cell proliferation and / or induction of differentiation by cyclindependent kinase (cdk)-inhibitor, e.g. olomoucin, butyrolactone-I, ii) induction of apoptosis by directing “abortive cell cycle”, or the transient upregulation of cdk activity, e.g. flavopiridol, and iii) countering the development of drug resistance by adjunctive administration of cdk-inhibitors with conventional anti-cancer drug, e.g., p21-gene transfer with cisplatin. Conclusively none of these three approaches by itself is satisfactory, and that the effective cancer therapies will require the administration of several agents and / or methods under the design of their synergistic effects.
Export Options
About this article
Cite this article as:
Dobashi Yoh, Takehana Takuo and Ooi Akishi, [General Articles] Perspectives on Cancer Therapy: Cell Cycle Blockers and Perturbators, Current Medicinal Chemistry 2003; 10 (23) . https://dx.doi.org/10.2174/0929867033456495
DOI https://dx.doi.org/10.2174/0929867033456495 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets Nutritional Control, Gene Regulation, and Transformation of Vascular Smooth Muscle Cells in Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets High Specificity in Response of the Sodium-Dependent Multivitamin Transporter to Derivatives of Pantothenic Acid
Current Topics in Medicinal Chemistry Is Senescence Reversible?
Current Drug Targets Recent Advances in the Development of Selective Small Molecule Inhibitors for Cyclin-Dependent Kinases
Current Topics in Medicinal Chemistry Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials
Current Pharmaceutical Design The Nature of Enzymes Involved in Uracil-DNA Repair: Isoform Charac-teristics of Proteins Responsible for Nuclear and Mitochondrial Genomic Integrity 1
Current Protein & Peptide Science Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Current Cancer Therapy Reviews Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development
Current Pharmaceutical Design Proteomic Classification of Breast Cancer
Current Drug Targets Role of Histone Acetylation in Cell Cycle Regulation
Current Topics in Medicinal Chemistry Silybin and Silymarin - New and Emerging Applications in Medicine
Current Medicinal Chemistry CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Protein Geranylgeranyltransferase Type 1 as a Target in Cancer
Current Cancer Drug Targets Heat Shock Proteins as Prognostic Markers of Cancer
Current Cancer Drug Targets Historical Spice as a Future Drug: Therapeutic Potential of Piperlongumine
Current Pharmaceutical Design Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site
Anti-Cancer Agents in Medicinal Chemistry Flavonoids with Therapeutic Potential in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry AKT Signaling in Regulating Angiogenesis
Current Cancer Drug Targets Gene Delivery for Cancer Therapy
Current Drug Delivery